scholarly journals Incidence and clearance of oral and cervicogenital HPV infection: longitudinal analysis of the MHOC cohort study

BMJ Open ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. e056502
Author(s):  
Andrew F Brouwer ◽  
Lora P Campredon ◽  
Heather M Walline ◽  
Brittany M Marinelli ◽  
Christine M Goudsmit ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Hpv Infection ◽  
Sexual Partners ◽  
Infection Prevalence ◽  
College Age ◽  
Adult Participants ◽  
Ann Arbor ◽  
Oral Hpv ◽  
The Mean ◽  
Mean Time

ObjectivesThe Michigan HPV and Oropharyngeal Cancer study aimed to evaluate patterns of oral and cervicogenital human papillomavirus (HPV) infection prevalence, incidence, and clearance as well as their relationship to sexual behaviours.DesignCohortSettingGeneral public in and around Ann Arbor, Michigan.Participants394 college-age and older-adult participants of both sexes provided oral samples, and 325 completed at least 2 visits. 130 who provided a cervicogenital samples, and 127 completed at least 2 visits.OutcomesIncidence and clearance rates as well as HRs for oral and cervicogenital HPV.ResultsOral HPV infections were transient, with only 16% of genotypes persisting to the next visit. The mean time to clearance of a genotype was 46 days (95% CI 37 to 58). In contrast, cervicogenital infections were more persistent, with 56% of genotypes persisting to the next visit. The mean time to clearance of a genotype was 87 days (95% CI 74 to 102). HPV vaccination was associated with reduced incidence of cervicogenital HPV infection (HR 0.63; 95% CI 0.47 to 0.83) but not oral HPV infection. Incidence of oral HPV infection was associated with 2+ recent deep kissing partners (HR 2.00; 95% CI 1.13 to 3.56). Incidence of both oral (HR: 1.70; 95% CI 1.08 to 2.68) and cervicogenital (HR 2.46; 95% CI 1.69 to 3.59) was associated with 2+ recent sexual partners.ConclusionsDetection of oral HPV was highly transient, but incidence was associated with recent deep kissing and sexual partners. Detection of cervicogenital HPV was more persistent, and incidence was positively associated with recent sexual partners and negatively associated with HPV vaccination.

scholarly journals Prevalence and determinants of oral and cervicogenital HPV infection: baseline analysis of the MHOC cohort study

2022 ◽  
Author(s):  
Andrew Brouwer ◽  
Lora P Campredon ◽  
Heather M Walline ◽  
Brittany M Marinelli ◽  
Christine M Goudsmit ◽  
...  
Keyword(s):  
Older Adult ◽  
Sexual Behaviors ◽  
Hpv Infection ◽  
Infection Prevalence ◽  
Full Cohort ◽  
College Age ◽  
Hpv Prevalence ◽  
Adult Participants ◽  
Ann Arbor ◽  
Oral Hpv

We determined baseline oral and cervicogenital human papillomavirus (HPV) prevalence and determinants of infection in the Michigan HPV and Oropharyngeal Cancer (MHOC) study. We enrolled 394 college-age and older-adult participants of both sexes in Ann Arbor, Michigan and the surrounding area. All participants provided an oral sample at baseline, and 130 females provided a cervicogenital sample. Samples were tested for 18 HPV genotypes using polymerase chain reaction (PCR) MassArray. Participants filled out sociodemographic and behavioral questionnaires. Prevalence ratios for HPV oral or cervicogenital prevalence by predictor variables were estimated in univariable log-binomial models. Analysis was conducted 2018-20. In the full cohort, baseline oral HPV prevalence was 10.0% for any detected genotype (among the 338 valid oral tests at baseline) and 6.5% for high-risk types, and cervicogenital prevalence was 20.0% and 10.8%, respectively (among the 130 first valid cervicogenital tests). Oral HPV prevalence did not vary by sex, with 10.5% of women and 9.0% of men having an infection. We found a high prevalence of oral and cervicogenital HPV infection among those reporting no recent sexual partners compared to those with a single recent sexual partner, but prevalence increased with the number of recent partners for most sexual behaviors. We observed an ecological fallacy masking the direction of impact of vaccination on HPV prevalence in the full cohort compared to the college-aged and older-adult populations considered separately. Substance use was not significantly associated with oral or cervicogenital HPV infection. Many studies report substantially higher oral HPV infection prevalence in men than in women. That difference may not be uniform across populations in the US.

scholarly journals Human papilloma virus (HPV) genotypes concordance between Iranian couples referrals

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Mehrdad Davarmanesh ◽  
Mehrouz Dezfulian ◽  
Mohammad Javad Gharavi ◽  
Sarang Younesi ◽  
Pourandokht Saadati ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Sexual Partners ◽  
Papilloma Virus ◽  
Hpv Dna ◽  
Hpv Genotypes ◽  
Sexual Couples ◽  
Males And Females ◽  
The Mean

Abstract Background Human Papilloma Virus (HPV) genotypes concordance among sexual couples has been evaluated in many investigations with considerable variations in the concordance. However, no such study has carried out between Iranian couples yet. Methods Urogenital specimen from both males and females of couples were taken and transferred to Nilou laboratory for molecular analysis. HPV DNA extraction and typing were carried out using cobas 4800 platform. Demographic and virological data were analyzed afterwards. Results One hundred fourteen couples were enrolled in the study. The mean age of participants were 36 ± 8 and 32 ± 7 for males and females, respectively. 64 (28%) of specimens were positive for at least one HPV genotype. The positive rates within genders were 30.7 and 25.4% for females and males, respectively with a considerable association (P value 0.021). Within the positive samples, 13(5.7%), 8 (7%) and 31(13.5%) were belonged to 16, 18 and other HR genotypes. 59 (51.8%) couples who were negative for HPV showed negative concordance. Of the total positive HPV patients (55 couples, 48.2%), 9 (16.3%) couples had positive concordance and the rest of 46 (83.7%) couples (either of spouse being negative and the other being positive for HPV) showed neither kinds of concordance. Conclusion Recognition of the dynamics of HPV infection not only in women, but in their sexual partners could impact the implementation of preventive measures like HPV vaccination for cervical cancer and other HPV-related diseases for both sexual partners.

Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the U.S.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6003-6003 ◽  
Author(s):  
Maura L. Gillison ◽  
Tatevik Broutian ◽  
Barry Graubard ◽  
Robert Pickard ◽  
Zhen-Yue Tong ◽  
...  
Keyword(s):  
Young Adults ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Vaccine Dose ◽  
Population Level ◽  
Hpv Infection ◽  
Vaccine Uptake ◽  
Infection Prevalence ◽  
The Us ◽  
Oral Hpv

6003 Background: The incidence of HPV-positive oropharyngeal cancers has risen in recent decades among US men. The potential impact of HPV vaccines on oral HPV infections has yet to be evaluated in efficacy-trials or surveillance studies. Methods: To evaluate the impact of prophylactic HPV vaccination on oral HPV infections in the US population, we conducted a cross-sectional study among men and women aged 18-33 years (n = 2,627) in the National Health and Nutrition Examination Survey, 2011-2014. We examined the effect of self-reported receipt of ≥1 vaccine dose on oral HPV infection (vaccine-types 16/18/6/11) prevalence among vaccinated vs. unvaccinated individuals. Additional outcomes included percent reduction in infection-prevalence among vaccinated individuals and population-level effectiveness of vaccination. Analyses accounted for the complex sampling design. Comparisons between vaccinated and unvaccinated individuals were conducted using binary logistic regression, with adjustment for age, gender, and race. Statistical significance was assessed using a quasi-score test. Results: During 2011-2014, 18.3% of the US population aged 18-33 years reported receipt of ≥1 HPV vaccine-dose prior to age 26 (29.2% in women and 6.9% in men; P< 0.001). The prevalence (population-weighted) of oral HPV16/18/6/11 infections was significantly reduced in vaccinated vs. unvaccinated individuals (0.11% vs. 1.61%; P= 0.008), corresponding to an estimated 88.2% (95%CI = 5.7%-98.5%) reduction in prevalence. Notably, oral HPV16/18/6/11 prevalence was significantly reduced in vaccinated vs. unvaccinated men (0.0% vs. 2.13%; P= 0.007). In contrast, prevalence for 33 non-vaccine HPV types was similar (3.98% vs. 4.74%; P= 0.24). Accounting for HPV vaccine-uptake, the population-level effectiveness of HPV vaccination on the burden of oral HPV16/18/6/11 infections was 17.0% overall, 25.0% in women and 6.9% in men. Conclusions: HPV vaccination substantially reduced vaccine-type oral HPV infection prevalence among young adults (ages 18-33 years) in the US population during 2011-2014. However, due to low vaccine uptake, population-level effectiveness was modest overall and particularly low in men.

scholarly journals Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States

2018 ◽  
Vol 36 (3) ◽  
pp. 262-267 ◽  
Author(s):  
Anil K. Chaturvedi ◽  
Barry I. Graubard ◽  
Tatevik Broutian ◽  
Robert K.L. Pickard ◽  
Zhen-Yue Tong ◽  
...  
Keyword(s):  
United States ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Population Level ◽  
The United States ◽  
Hpv Infection ◽  
Vaccine Uptake ◽  
The Us ◽  
Oral Hpv ◽  
Level Effect

Purpose The incidence of human papilloma virus (HPV)–positive oropharyngeal cancers has risen rapidly in recent decades among men in the United States. We investigated the US population–level effect of prophylactic HPV vaccination on the burden of oral HPV infection, the principal cause of HPV-positive oropharyngeal cancers. Methods We conducted a cross-sectional study of men and women 18 to 33 years of age (N = 2,627) within the National Health and Nutrition Examination Survey 2011 to 2014, a representative sample of the US population. Oral HPV infection with vaccine types 16, 18, 6, or 11 was compared by HPV vaccination status, as measured by self-reported receipt of at least one dose of the HPV vaccine. Analyses accounted for the complex sampling design and were adjusted for age, sex, and race. Statistical significance was assessed using a quasi-score test. Results Between 2011 and 2014, 18.3% of the US population 18 to 33 years of age reported receipt of at least one dose of the HPV vaccine before the age of 26 years (29.2% in women and 6.9% in men; P < .001). The prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated individuals (0.11% v 1.61%; Padj = .008), corresponding to an estimated 88.2% (95% CI, 5.7% to 98.5%) reduction in prevalence after model adjustment for age, sex, and race. Notably, the prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated men (0.0% v 2.13%; Padj = .007). Accounting for vaccine uptake, the population-level effect of HPV vaccination on the burden of oral HPV16/18/6/11 infections was 17.0% overall, 25.0% in women, and 6.9% in men. Conclusion HPV vaccination was associated with reduction in vaccine-type oral HPV prevalence among young US adults. However, because of low vaccine uptake, the population-level effect was modest overall and particularly low in men.

Oral HPV prevalence in women positive for cervical HPV infection and their sexual partners: a German screening study

2016 ◽  
Vol 273 (7) ◽  
pp. 1933-1942 ◽  
Author(s):  
Ralf B. Uken ◽  
Oliver Brummer ◽  
Carolin von Schubert-Bayer ◽  
Thomas Brodegger ◽  
Ingo U. Teudt
Keyword(s):  
Hpv Infection ◽  
Sexual Partners ◽  
Hpv Prevalence ◽  
Screening Study ◽  
Oral Hpv

scholarly journals Awareness of oral and genital human papillomavirus (HPV) infection in young adolescents prior to gender-neutral vaccination

2020 ◽  
pp. bmjsrh-2019-200410
Author(s):  
Gillian Knight ◽  
Ben Roberts
Keyword(s):  
Human Papillomavirus ◽  
Oropharyngeal Cancer ◽  
Healthcare Professionals ◽  
Hpv Vaccination ◽  
Intervention Strategy ◽  
Hpv Infection ◽  
Similar Proportion ◽  
Transmitted Infection ◽  
Oral Hpv ◽  
The Impact

IntroductionOral human papillomavirus (HPV) and oropharyngeal cancer prevalence are increasing, particularly in men. Raising greater awareness of male HPV disease is perceived as an important intervention strategy. This study investigated the effectiveness of HPV education on adolescents’ perception of HPV disease and the impact of HPV vaccination on their sexual health.MethodsAn HPV questionnaire was completed by 357 UK-based adolescents, aged 12–13 years.ResultsMost adolescents knew HPV causes cervical cancer and HPV vaccination prevents this. A minority acknowledged HPV causes other genital cancers, with under one-fifth knowing HPV causes genital warts. Adolescents’ awareness of HPV transmission activities were limited. There was very poor awareness of oral HPV infection or HPV-induced oropharyngeal cancer. Half of the participants stated HPV vaccination reduced their concerns about sexually transmitted infection contraction. Over half the males said they may take more sexual risks following vaccination, while a similar proportion of females did not expect their partner to take more risks.ConclusionsAdolescents had little awareness of male HPV infection and the role HPV vaccination can play in preventing these diseases. With variable rates of HPV vaccination uptake in males reported worldwide, this study indicates that in the UK greater emphasis on male HPV disease within educational information is required, to raise better awareness of how HPV affects both genders. As both genders preferred to receive education via healthcare professionals, educating a wider range of healthcare professionals on oral HPV could help facilitate awareness of HPV’s role in head and neck cancer.

Prevalence of oral HPV infection in cervical HPV positive women and their sexual partners

2019 ◽  
Vol 299 (6) ◽  
pp. 1659-1665 ◽  
Author(s):  
T. K. Eggersmann ◽  
K. Sharaf ◽  
P. Baumeister ◽  
C. Thaler ◽  
C. J. Dannecker ◽  
...  
Keyword(s):  
Hpv Infection ◽  
Sexual Partners ◽  
Oral Hpv

scholarly journals Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e046928
Author(s):  
Lisa M Jamieson ◽  
Gail Garvey ◽  
Joanne Hedges ◽  
Cathy Leane ◽  
Isaac Hill ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Indigenous Australians ◽  
Health State ◽  
Hpv 16 ◽  
Oral Hpv ◽  
Hpv Types

PurposeOur aims are to: (1) estimate prevalence, incidence, clearance and persistence of oral human papillomavirus (HPV) infection among Indigenous Australians; (2) identify risk factors associated with oropharyngeal squamous cell carcinoma (OPSCC)-related HPV types (HPV 16 or 18); (3) develop HPV-related health state valuations and; (4) determine the impact on OPSCC and cervical cancers, and the cost-effectiveness of extending publicly-funded HPV vaccination among Indigenous Australians.ParticipantsParticipants were recruited from February 2018 to January 2019. Twelve-month follow-up occurred from March 2019 to March 2020. Participants provided socio-demographic characteristics, health-related behaviours including tobacco and alcohol use and sexual history. Health state preferences in regard to HPV vaccination, knowledge regarding HPV infection, OPSCC and cervical cancer were collected using a two-stage standard gamble approach. Participants provided saliva samples and DNA for microbial genotyping was extracted.Findings to dateOf the 910 participants who were positive for β-globin at baseline, 35% had any oral HPV infection. The most prevalent HPV types were 13 or 32 (Heck’s disease; 23%). The second most prevalent types were associated with OPSCC (HPV 16 or 18; 3.3%). Of the 645 participants who were positive for β-globin at 12-month follow-up, 43% had any HPV infection. Of these, 33% were HPV types 13 or 32 and 2.5% were HPV 16 or 18. Some 588 participants had β-globin positive oral samples at baseline and 12-month follow-up. The prevalence of any oral HPV infection increased from 34% at baseline to 44% at 12-month follow-up; due to increases in HPV types 13 or 32 (20% at baseline and 34% at 12-month follow-up).Future plansFurther funding will be sought to continue follow-up of this cohort, and to include (after a full medical history) a thorough clinical examination of the external head and neck; a complete oral examination and examination of the oropharynx. Blood tests for early stage OPSCC will also be undertaken.

scholarly journals 1100National prevalence of oral HPV infection in vaccinated and unvaccinated young adults in Brazil

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Natália Luiza Kops ◽  
Juliana Comerlato ◽  
Isabel Bandeira ◽  
Marina Bessel ◽  
Ana Goretti Kalume Maranhão ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Hpv Infection ◽  
Quadrivalent Vaccine ◽  
Sampling Weights ◽  
Cross Sectional ◽  
Hpv Prevalence ◽  
Significant Difference ◽  
Oral Hpv ◽  
Hpv Types ◽  
Putative Precursor

Abstract Background Prophylactic HPV vaccination has been recommended for the prevention of cancers caused by HPV infection. Nevertheless, may be reduce the oral HPV prevalence, the putative precursor to oral squamous cell carcinoma. This study aimed to report the prevalence of oral HPV among vaccinated and unvaccinated women and men aged 16 to 25 years who use the public health system. Methods POP-Brazil study is a cross-sectional, multicentric survey. Participants were recruited from 119 public primary care units distributed throughout all 27 capitals of Brazil. Trained health professionals applied a face-to-face interview. Oral sample was collected through mouthwash and gargle cycles. HPV genotyping was performed in a central lab using the Roche PCR-based Linear Array genotyping test. Sampling weights by sex and age were applied to the data. Results Oral HPV samples were collected from 5,684 participants; 613 (8.93%) vaccinated against HPV, in which 86.57% were women. Among women, the overall HPV prevalence was significantly lower in those vaccinated [0.43% (95% CI, 0.03-0.83)] than unvaccinated [1.65% (95% CI, 0.97– 2.33] (p &lt; 0.01). Among men, no significant difference was found. All vaccinated individuals were negative to the HPV types present in the quadrivalent vaccine (6, 11, 16, and 18). Conclusion Vaccinated individuals had a lower prevalence of overall oral HPV besides the null infection by 6, 11, 16, and 18 HPV types showing another benefit of this cancer prevention measure. Due to the low prevalence of oral HPV, type specific analysis demand higher number of positive participants.

scholarly journals Prevalence of Vaginal HPV Infection Among Adolescent Girls in Jos, North-Central Nigeria

2021 ◽  
Author(s):  
Nanma T. Cosmas ◽  
Lohya Nimzing ◽  
Daniel Egah ◽  
Ayo Famooto ◽  
Sally N. Adebamowo ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Hpv Infection ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Middle Income ◽  
North Central ◽  
Middle Income Countries ◽  
Vaginal Swabs ◽  
The Mean ◽  
High Risk Hpv

Abstract Purpose: Knowledge of the prevalence of HPV infection among adolescents is essential to determining the best age for introduction of HPV vaccine, monitoring vaccine efficacy and giving insight into determinants of persistent high-risk HPV infection, a necessary cause of cervical cancer. Yet, there’s been limited studies in low-and-middle-income countries.Methods: In this cross-sectional study, we randomly selected 205 girls, aged 9–20 years, from 10 schools. We obtained informed consent and assent, collected data and trained participants who self-collected vaginal samples using swab stick. We genotyped HPV using SPF10-DEIA/LiPA25 and analyzed data using Stata 14®.Results: The mean (SD) age of the girls was 14.9 (2.3) years. We found HPV in 13.2% of vaginal swabs. The earliest age at which anyHPV and hrHPV infections were detected was 10 and 12 years respectively. The prevalence of any HPV peaked at 16 and 17 years, hrHPV at 16 years, lrHPV at 17 and 18 years and multiple hrHPV 18 years of age. The prevalence of hrHPV infection was 1.5% among the 9–12 years age group, 2.9% among 13–16 years and 3.4% among 17–20 years old. The commonest hrHPV types detected were 52 (3.9%), 18 (1.5%) and 51 (2.4%). The most common lrHPV types was 6 (2.9%).Conclusion: The prevalence of HPV infection in these urbanized young girls in Nigeria is high and commences after 9 years of age. HPV vaccination in this population should start at 9 years of age or younger to prevent establishment of persistent HPV infection.

Sign in / Sign up

Export Citation Format

Share Document